Aurora EV ICD (DVEA3E4)
Medtronic, Inc. · Decision date Dec 3, 2025
What did the FDA decide?
FDA records P220012/S062 as a supplement to PMA P220012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 3, 2025.
FDA approval order statement
to implement an alternate supplier of a carbon ink component used in ICD and CRT-D capacitor assemblies
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 3, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220012/S062
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWS
- Decision code
- OK30
- Decision date
- Dec 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Medtronic, Inc.
- Product code
- LWS
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220012/S055 · Related supplement
Aurora EV-ICD System
P220012/S056 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S057 · Related supplement
Aurora EV-ICD System (DVEA3E4)
P220012/S054 · Related supplement
Aurora EV-ICD System
P220012/S058 · Related supplement
Aurora EV ICD (DVEA3E4)
P220012/S059 · Related supplement
Aurora EV ICD (DVEA3E4)
P220012/S062 received
Application receipt date recorded by FDA.
P220012/S060 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S062 · FDA decision
30-Day Notice
P220012/S061 · Related supplement
Aurora EV-ICD System
P220012/S063 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S064 · Related supplement
Aurora EV-ICD System
P220012/S066 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S065 · Related supplement
Aurora EV ICD
P220012/S067 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S068 · Related supplement
Aurora EV ICD; Epsila EV Extravascular Lead
P220012/S070 · Related supplement
Epsila EV Extravascular Lead
P220012/S071 · Related supplement
Aurora EV ICD, Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD, Evera MRI DF-1 ICD, Evera MRI ICD
P220012/S072 · Related supplement
Aurora EV-ICD
P220012/S069 · Related supplement
Aurora EV ICD DVEA3E4
P220012/S073 · Related supplement
Aurora EV ICD
P220012/S074 · Related supplement
Aurora EV ICD (DVEA3E4)
P220012/S075 · Related supplement
Aurora EV-ICD (DVEA3E4)
Timeline entries are records held by MedtechLedger for P220012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Aurora EV-ICD SystemP220012/S055 | Medtronic, Inc. | PMA supplement | Jul 29, 2025 | FDA |
Aurora EV ICD DVEA3E4P220012/S056 | Medtronic, Inc. | PMA supplement | Aug 12, 2025 | FDA |
Aurora EV-ICD System (DVEA3E4)P220012/S057 | Medtronic, Inc. | PMA supplement | Sep 5, 2025 | FDA |
Aurora EV-ICD SystemP220012/S054 | Medtronic, Inc. | PMA supplement | Sep 11, 2025 | FDA |
Aurora EV ICD (DVEA3E4)P220012/S058 | Medtronic, Inc. | PMA supplement | Oct 3, 2025 | FDA |
Aurora EV ICD (DVEA3E4)P220012/S059 | Medtronic, Inc. | PMA supplement | Oct 28, 2025 | FDA |
Aurora EV ICD DVEA3E4P220012/S060 | Medtronic, Inc. | PMA supplement | Dec 3, 2025 | FDA |
Aurora EV-ICD SystemP220012/S061 | Medtronic, Inc. | PMA supplement | Dec 15, 2025 | FDA |
Aurora EV ICD DVEA3E4P220012/S063 | Medtronic, Inc. | PMA supplement | Jan 5, 2026 | FDA |
Aurora EV-ICD SystemP220012/S064 | Medtronic, Inc. | PMA supplement | Jan 23, 2026 | FDA |
Aurora EV ICD DVEA3E4P220012/S066 | Medtronic, Inc. | PMA supplement | Feb 10, 2026 | FDA |
Aurora EV ICDP220012/S065 | Medtronic, Inc. | PMA supplement | Feb 11, 2026 | FDA |
Aurora EV ICD DVEA3E4P220012/S067 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
Aurora EV ICD; Epsila EV Extravascular LeadP220012/S068 | Medtronic, Inc. | PMA supplement | Mar 6, 2026 | FDA |
Epsila EV Extravascular LeadP220012/S070 | Medtronic, Inc. | PMA supplement | Apr 15, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Apr 28, 2026 | FDA | |
Aurora EV-ICDP220012/S072 | Medtronic, Inc. | PMA supplement | Apr 30, 2026 | FDA |
Aurora EV ICD DVEA3E4P220012/S069 | Medtronic, Inc. | PMA supplement | Jun 25, 2026 | FDA |
Aurora EV ICDP220012/S073 | Medtronic, Inc. | PMA supplement | Jul 16, 2026 | FDA |
Aurora EV ICD (DVEA3E4)P220012/S074 | Medtronic, Inc. | PMA supplement | Jul 31, 2026 | FDA |
Aurora EV-ICD (DVEA3E4)P220012/S075 | Medtronic, Inc. | PMA supplement | Jul 31, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. NE, Mv Mv S11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P220012/S062
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






